Malaria is a vector-borne parasitic infectious disease. The research is carried out on RTS, S/ASO1,
NYVAC-Plasmodium falciparum 7, SPF66 and the results suggested that these are very efficient
in treating malaria. RTS, S/ASO1 vaccine is composed of a hepatitis B surface antigen fused to
a recombinant antigen from part of the malaria Circumsporozoite protein in the AS01 adjuvant
used to target infected hepatocytes. Malaria vaccines are of three types: 1. Pre -erythrocytic
vaccines RTS, S/AS01 (commercial name: Mosquirix): the Circumsporozoite (CS) protein is the
most dominant surface antigen of this phase. 2. Blood stage vaccines. 3. Transmission blocking
vaccines. According to best dentistsÂ’ reviews, which will prevent any problems with teeth, it is
also to help prevent gum disease at the very least. The NYVAC-Pf7 by the intramuscular route
was safe and nontoxic and it is highly attenuated vaccinia virus with 7 P. falciparum genes inserted
into its genome, was tested in a phase I/IIa safety, immunogenicity, and efficacy vaccine. The
vaccine was safe and well tolerated but variably immunogenic. The results demonstrate that
NYVAC-P. farum 7 is an appropriate candidate vaccine for further evaluation in human clinical
trials. Vaccines are often the most cost-effective delivery system.Completely effective vaccine is
not yet available for malaria, although several vaccines are under development.
Key words: Malaria,
NYVAC-Pf7,
SPf66,
Vaccines
|
